Prospective observational study evaluates methotrexate effectiveness in unruptured tubal ectopic pregnancy, suggesting a safe non-surgical treatment option.
Background: Ectopic pregnancy is a major cause of maternal morbidity & mortality during early gestation. Methotrexate therapy offers a conservative, fertility-preserving alternative for unruptured tubal ectopic pregnancies; however, outcomes vary across populations. Objectives: This study aimed to evaluate the clinical outcomes and side effects of methotrexate in treating unruptured tubal ectopic pregnancy at a tertiary care hospital in Bangladesh. Methods & Materials: This prospective observational study was conducted at the Department of Obstetrics and Gynecology, Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh, from July 2024 to June 2025. A total of 100 hemodynamically stable women diagnosed with unruptured tubal ectopic pregnancy were treated with intramuscular methotrexate (50 mg/m²). Serum β-hCG was monitored on days 4 and 7; success was defined as a ≥15% decline between these intervals and complete resolution without surgery. Data were analyzed using SPSS version 25.0. Results: The overall treatment success rate was 82%, with 72% of patients achieving resolution after a single dose and 10% requiring a second dose. Mean β-hCG resolution time was 31.6 ± 8.7 days. Significant predictors of success included baseline β-hCG levels <5000 mIU/mL (p = 0.02) and ectopic mass size <4.0 cm (p = 0.03). Adverse effects were mild, with abdominal pain (28%) and nausea/vomiting (22%) being the most common. Conclusion: Methotrexate is a highly effective, safe, and well-tolerated non-surgical option for appropriately selected patients with unruptured tubal ectopic pregnancy in tertiary care settings.
No takes yet. Share an insight, caveat, or question.
Rashed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: